



Welcome to the
Imricor Annual Meeting

Thursday, 6 May 2021 (AEST)
Wednesday, 5 May 2021 (CDT)




Please submit questions at any time throughout the meeting

When the Question function is available, the Q&A icon will appear at the top of the app




To send in a question, click in the 'Ask a question' box, type your question and press the send arrow



Your question will be sent immediately for review




Received





Voting online at the virtual meeting

When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen



To vote simply select the direction in which you would like to cast your vote. The selected option will change colour




For

Against

Abstain

There is no submit or send button, your selection is automatically recorded. You can change your mind or cancel your vote any time before the poll is closed

330-481-282

i   

You have voted on 0 of 1 items

*Please complete the questions below.
Responses are sent individually.
There is no final 'Send' or 'Submit' button.*

Resolution 1

Select a choice to send.

For Against Abstain

CANCEL



Imricor's Board of Directors



Steve Wedan
President and CEO,
and Chair



Mark Tibbles
Deputy Chair and Lead
Independent Director



Anita Messal
Non-executive Director



Peter McGregor
Non-executive Director

Chair's Address






Managing through COVID-19

- Due to hospital closures associated with strict COVID-19 containment measures implemented across key target geographies of Germany and the Netherlands, Imricor experienced delays in signing agreements with new clinical sites in the last quarter of 2020
- Lower consumable sales as a result of lower procedure volumes due to COVID-19 related hospital closures and restrictions on elective surgery
- Imricor is working closely with contracted sites to schedule installation, training and the commencement of cases as soon as restrictions ease
- Training and installation teams in Europe supported by US based teams are well placed as COVID-19 restrictions ease
- Redeployed members of the manufacturing workforce to product development, with a focus on building products for future clinical trials to support expanded indications and geographies
- Delivered online events and education seminars in lieu of industry trade events



COVID-19 situation in key target geographies


Daily cases (7 day average) to 30 Apr 2021



- Signed five new agreements in a six-week period during September and October
- Hard lock downs in mid-December resulted in strict and prolonged containment measures, causing delay in our site roll out plans
- Vaccinations combined with falling daily case rates resulted in restrictions easing in the months of February and March
- Elective procedures were once again allowed in certain geographies
- We saw the first cases being carried out at Maastricht University Medical Centre (MUMC+) in mid-February and cases recommencing at Leipzig Heart Centre in March
- Signed Helios Hospital Berlin-Buch as Imricor's tenth iCMR site



Vaccination situation in key target geographies



- A new wave of COVID-19 combined with disappointing vaccination rollout in late March / early April resulted in the reinstatement of stricter containment measures, including the prohibition of elective procedures
- Vaccinations are now well underway across Europe with over 20% of the population in our key target geographies having received at least one dose of the vaccine
- As vaccinations continue to accelerate, elective procedures are expected to recommence in the second quarter of 2021



Partnering to drive growth in clinical sites

Imricor entered into a number of agreements in 2020 that promote future iCMR site adoption



- A worldwide leading manufacturer of MRI equipment
- Non-exclusive collaborative sales distribution agreement
- Enables the sale of Imricor's capital product, Advantage-MR EP Recorder/Stimulator System as part of Philips comprehensive iCMR lab installation package¹
- Enables the extensive Philips sales force to drive iCMR site adoption
- Imricor continues to be the exclusive provider of its consumable devices



- Largest Group Purchasing Organisation in Germany, with 600 cooperating hospitals and medical institutions across Germany & Switzerland
- Imricor products included in approved catalogue, establishing pricing and eliminating time consuming contract negotiations
- Streamlines access to ~80 sites that perform cardiac ablations for sales and marketing activities



- Leading provider of innovative optical communication solutions for MRI applications
- Facilitates the introduction of the IMROC™ Wireless Multichannel Communication System to Imricor customers
- Innovative noise cancelling communication technology supporting iCMR adoption
- Establishes an important sales channel ensuring availability as new sites are launched
- Referral fee-based agreement



- Leading German producer of radiofrequency ablation generators
- Will sell Osypka's HAT 500 radiofrequency ablation generator system to customers for use in iCMR ablation procedures
- The HAT 500 is compatible with Imricor's Advantage-MR EP Recorder/Stimulator, replacing the discontinued Abbott IBI T11 ablation generator.




- Australian-owned medical distribution company with 40 years of experience in the Australian medical industry as a provider of medical consumables, contrast media and capital equipment
- Exclusive distributor of Imricor's consumable products in Australia & NZ
- Non-exclusive distributor of Imricor's capital equipment
- Will help facilitate the necessary regulatory approvals for TGA approval



Developing product lines to support expanded indications & margin improvement

Diagnostic Catheter



A diagnostic catheter can sense electrical signals flowing through the heart and provide cardiac stimulation but is not used for ablation. A diagnostic and ablation catheter are each required to perform atrial flutter procedures - currently sold by Imricor in a two-catheter set comprising two ablation catheters.

- Development complete and submitted for CE mark certification
- Scaled down second-generation Vision-MR ablation catheter
- Utilising advancements from the next generation ablation catheter to create a more consistent product line for physicians and reduce production costs to drive a higher gross margin
- Aiming for late 2021 or early 2022 commercial release, pending CE mark approval

The steerable sheath and transseptal needle are intended to be used together in procedures where access to the left side of the heart is required and the physician opts to access the left side by crossing the intra-atrial septum

Steerable Sheath and Transseptal Needle



- Development phase
- Fully staffed execution
- On track to be ready for VT clinical trials in 2021



Lab rollout plans underpinned by strong pipeline

10 sites with agreements to purchase Imricor's products



Nine clinical sites now contracted across Germany, The Netherlands & France

- Dresden Heart Centre, Germany, a training Centre of Excellence
- Haga Hospital, The Netherlands
- Amsterdam University Medical Centre, The Netherlands
- Helios Leipzig Heart Centre, Germany, a training Centre of Excellence
- Rhön Clinic Bad Neustadt Campus, Germany
- Maastricht University Medical Centre, The Netherlands
- South Paris Cardiovascular Institute, France
- Lübeck University Heart Centre, UKSH, Germany
- Münster University Hospital, Germany
- Helios Hospital Berlin-Buch, Germany

Initial sites (e.g. Dresden, Leipzig) also designated as training Centres of Excellence for sites that follow

Strong pipeline



- Discussions well advanced across several sites, many at final stage of review and execution
- Strong and growing pipeline of potential sites supported by increasing awareness and education of Imricor's product
- Agreement with Sana GPO provides access to ~80 sites for sales & marketing
- Further enhanced by Philips sales distribution agreement and collaborative relationship with Siemens to drive site adoption
- A well-developed longer-term pipeline aligned with capital cycles of clinical sites
- Expecting to recommence signing new agreements during the second quarter, accelerating in the second half of 2021



A phased approach to Geographic Expansion

Europe

CE mark received
We have established sales force
targeting Germany and the
Netherlands

Remain on track to targeting a
clinical trial for VT Ablations
in late 2021 – early 2022


United States

FDA strategy well advanced
Discussion with FDA underway
Remain on track to targeting a
clinical trial in 2021-2022

Australia

Entered into a distribution
agreement with a local agent to
help facilitate TGA approval and
act as an agent for Imricor's
products.


Detailed approval strategy in
planning phase.





Continued investment in business capability and capacity to deliver growth

Workforce growth continues to expand capability across the company with 27 new hires in 2020 to support commercialisation and growth strategies, including hires from high calibre organisations within the med-tech sector



27 new hires 2020 15 new hires 2021 2019 team



Our focus for the year ahead

Imricor's focus for 2021 is on accelerating its product launch throughout the EU while pursuing growth opportunities that position the company strongly in the coming years

Commercialisation

- Continued site adoption with focus on acceleration in the second half of 2021
- Increased utilisation of the Philips sales force to drive the pipeline of iCMR labs
- Ongoing development of sirte pipeline through Imricor's marketing activities and collaboration with Siemens

Products

- Submit second-generation ablation catheter for CE mark approval
- Submit diagnostic catheter for CE mark approval
- Steerable sheath and transseptal needle ready for clinical trials that support expanded indications

Growth Initiatives

- Progress regulatory approvals to expand into Australia and the US
- Advance strategy around clinical trials expanding indications in Europe
- Progress development of MRI compatible biopsy system
- GM improvement initiatives to deliver benefits in future years



Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements” within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled ‘Risk factors’ in Imricor’s prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.